Devonian Health Group Inc (GSD : TSX-V)
Common Stock
$9.25
CAD
-0.50 (-5.13%)
Last updated: 2026-06-26
GSD
Devonian Health Group Inc
WealthAwesomePerformance
1 Day
-5.13%
1 Week
-11.90%
1 Month
-17.04%
YTD
-18.86%
Key Statistics
Market Cap
$25.72M
52W High
$15.00
52W Low
$0.19
P/E Ratio
-
50 Day MA
$10.77
200 Day MA
$11.30
Beta
1.21
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/26/2026 | $9.25 | $9.25 | $9.25 | $9.25 | $9.25 | 112 |
| 6/25/2026 | $9.75 | $9.75 | $9.75 | $9.75 | $9.75 | 0 |
| 6/24/2026 | $9.75 | $9.75 | $9.75 | $9.75 | $9.75 | 0 |
| 6/23/2026 | $9.75 | $9.75 | $9.75 | $9.75 | $9.75 | 100 |
| 6/12/2026 | $10.50 | $10.50 | $10.50 | $10.50 | $10.50 | 1,510 |
| 6/11/2026 | $11.00 | $11.15 | $10.00 | $10.00 | $10.00 | 1,800 |
| 5/25/2026 | $11.15 | $11.15 | $11.15 | $11.15 | $11.15 | 0 |
| 5/8/2026 | $11.15 | $11.15 | $11.15 | $11.15 | $11.15 | 2,600 |
| 5/1/2026 | $10.00 | $10.00 | $10.00 | $10.00 | $10.00 | 100 |
| 4/23/2026 | $11.00 | $11.90 | $11.00 | $11.90 | $11.90 | 200 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GSD's historical volatility
30-Day Vol
122.8%
Annualized
90-Day Vol
133.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$7.74
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.72 | C$5.71 – C$13.31 |
| 60 trading days | C$8.21 | C$4.51 – C$14.95 |
| 90 trading days | C$7.74 | C$3.72 – C$16.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Devonian Health Group Inc
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.
Financials
- Revenue (TTM)
- $10.18M
- EBITDA
- $-4.08M
- Profit Margin
- -88.16%
- ROE (TTM)
- -83.36%
- EPS (Diluted)
- -3.47
- Book Value
- 2.86
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-60
Jan 22, 2026
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About GSD
Articles Featuring GSD.V
Latest articles and analysis covering GSD.V
